West Pharmaceutical Services, Inc. - 2011 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: West Pharmaceutical Services, Inc.
Reporting Period: Fiscal year ended December 31, 2011
Business Overview: West is a global manufacturer of components and systems for the packaging and delivery of injectable drugs. Operations are organized into two reportable segments: Pharmaceutical Packaging Systems (stoppers, seals, closures) and Pharmaceutical Delivery Systems (safety systems, auto-injectors, contract manufacturing). The company serves leading global pharmaceutical, biotechnology, and medical device companies. As of December 31, 2011, the company employed approximately 6,300 people worldwide.
Key Financial Metrics (2011)
| Metric | 2011 Value | 2010 Value |
|---|---|---|
| Net Sales | $1,192.3 million | $1,104.7 million |
| Gross Profit | $339.3 million | $318.1 million |
| Gross Margin | 28.5% | 28.8% |
| Operating Profit | $109.6 million | $90.7 million |
| Net Income | $75.5 million | $65.3 million |
| Diluted EPS | $2.16 | $1.89 |
| Operating Cash Flow | $130.7 million | $138.3 million |
| Total Debt | $349.4 million | $358.4 million |
| Cash and Equivalents | $91.8 million | $110.2 million |
| Working Capital | $228.8 million | $266.9 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 7.9% year-over-year. Excluding favorable foreign currency effects ($30.2 million), organic sales grew 5.2%, driven by volume increases (3.9%) and price increases (1.3%).
- Segment Performance: Packaging Systems sales rose 9.2% to $857.4 million, while Delivery Systems sales increased 3.9% to $336.7 million.
- Profitability: Operating profit increased 20.8% to $109.6 million. However, gross margin decreased 0.3 percentage points primarily due to increased raw material costs (natural rubber, synthetic polymers) and wage increases, partially offset by price hikes and a temporary raw material surcharge implemented in July 2011.
- Restructuring: Restructuring charges decreased significantly to $5.3 million in 2011 compared to $15.9 million in 2010, as the company executed a plan approved in December 2010 to close a U.S. plant and reduce operations in England.
- Foreign Currency: A weaker U.S. dollar provided a favorable impact of $30.2 million on net sales and $4.5 million on operating profit.
Guidance, Outlook, and Risks
Outlook: Management anticipates continued revenue improvement in 2012, driven by high-value packaging and prefilled syringe components. Modest growth is expected from proprietary devices as development continues on the SmartDose electronic patch injector and Daikyo Crystal Zenith products. Capital spending for 2012 is projected between $135 million and $155 million, including $40 million for a new corporate office and research building.
Key Risks and Contingencies:
- Raw Material Volatility: Prices for elastomers and plastics are cyclical and linked to hydrocarbon prices. While a surcharge was implemented, there is a lag in passing costs to customers.
- Foreign Exchange: Over 50% of sales are generated outside the U.S. Fluctuations in the Euro, British Pound, and other currencies significantly impact reported results.
- Regulatory Environment: Compliance with FDA and international regulations is costly and time-consuming. Changes in healthcare reform (e.g., PPACA) could impact customer demand and pricing.
- Supply Chain: Reliance on single-source suppliers for critical raw materials creates supply interruption risks.
- Pension Obligations: The company has a net pension underfunded balance of $106.6 million as of year-end 2011, up from $71.2 million in 2010, due to actuarial losses and lower discount rates.
Investor Verification Checklist
- Raw Material Cost Pass-Through: Verify the effectiveness of the temporary raw material surcharge and the ability to sustain price increases in 2012 to offset inflation.
- Foreign Currency Exposure: Monitor exchange rate trends, particularly the Euro and British Pound, given that 54% of sales are international.
- Restructuring Completion: Confirm the realization of cost savings from the 2010 restructuring plan and the status of the remaining $1.9 million in expected charges for 2012.
- Capital Expenditures: Track progress on the new corporate office and research building ($36.3 million contract) and the China compression-molding plant to ensure they stay within the $135-$155 million budget.
- Pension Funding: Review the $19.8 million expected pension contribution for 2012 and the impact of changing discount rates on future expenses.
- Order Backlog: Note the order backlog of $289.8 million at year-end, all expected to be filled in 2012, as an indicator of near-term revenue visibility.